Top 20 Medical VC Funds & Investors in Norway (June 2026)

Portfolio highlights

• APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
• Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
• Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Portfolio highlights

• Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
• Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
• Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is

Portfolio highlights

• Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
• Biolinq — Introducing a revolutionary platform for metabolic health.
• Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Portfolio highlights

• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy'​ is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
• Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.

Portfolio highlights

• Sonair — Sonair is an award-winning deep tech startup building a breakthrough, patented 3D ultrasonic sensor that enables true machine autonomy by making robots safe, affordable, and efficient. Sonair was spun out from a leading European independent research organization, SINTEF, to exploit deep science-to-tech advancements in ultrasonics andMicro-ElectroMechanical Systems (MEMS). Using this technology, the company is delivering a sensor that will transform a robot’s vision from 2D to 3D, offering a significantly improved safety performance over traditional vision systems while cutting costs by 50-80%. The company, based in Oslo, Norway, was founded in 2022 by an experienced team of serial entrepreneurs led by Knut Sandven, former CEO of GasSecure.
• Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
• Kongsberg Ferrotech — Kongsberg Ferrotech offers game-changing robotic services for inspection, repair, and maintenance (IRM) of underwater installations

Portfolio highlights

• Nofence — Manage your livestock from anywhere with GPS collars and a simple app. Unlock more acres, cut fencing costs, and run your operation on your terms.
• 1X — At Halodi Robotics we are passionate about robots. Our mission is to bring capable humanoid robots to everyone. We develop safe, capable and affordable robots that help human beings live better lives!
• Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.

Portfolio highlights

• MiroBio — MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control.
• Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
• Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.

Portfolio highlights

• GlucoSet — GlucoSet develops tools for accurate continuous glucose monitoring in Intensive Care Units, to reduce patient mortality and hospital costs.
• BOYDSense — BOYDSense specializes in developing non-invasive and affordable tools for measuring critical biomarkers via the exhaled breath. The company provides breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using it to diagnose and monitor chronicdiseases.It was founded in 2015 and headquartered in South San Francisco, California.
• Luna Diabetes — Luna Diabetes offers smart insulin delivery for pen users, designed for safe overnight use so you can wake up rested and in control.

Portfolio highlights

• ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
• Avalyn Pharma — Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novelinhaled therapeutics.Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.
• Ventyx Biosciences — Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions.

Portfolio highlights

• GlucoSet — GlucoSet develops tools for accurate continuous glucose monitoring in Intensive Care Units, to reduce patient mortality and hospital costs.
• Screenful — Screenful is the easiest way to visualise your project progress using data from Jira, Trello, Asana, Github & Gitlab. Save time and get all the metrics you need at a glance with automated dashboards, custom charts and predictive reporting all in one place.

Portfolio highlights

• CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
• Genetic Analysis — Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications.
• Stingray Marine Solutions — Stingray Marine Solutions is a Norwegian technology firm that produces a laser unit which, when lowered into salmon farming pens, kills sea lice. It is based on entrepreneur Esben Beck’s patented idea in 2010 for salmon louse removal using camera vision and laser. It all started with Esben Beck and a lathe in his basement in 1999. After more than10 years of deliveries to oil, gas and offshore companies, he decided to invest in his own products. He decided to found and develop his own salmon louse project, where design, production, software development, testing, and installation were carried out by using in-house resources.Stingray is based in Oslo, Norway.

Portfolio highlights

• Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
• OpenCloud — Our cloud native software solutions dramatically improve operator business models and help quickly create new revenue-generating services.
• Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.

Portfolio highlights

• Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Portfolio highlights

• Innomost — Innomost develops and produces high-value bioactive ingredients from forest industry side streams that enable customers to make innovations in the cosmetic beauty industry. Its current product portfolio consists of birch charcoal powder, birch bark powder, betulin, suberin, and azelaic acid, which can trigger innovation in all cosmetic productcategories including skincare, haircare, body care, decorative cosmetics, and oral care.
• Bahn Express — Bahn Express is a global car transportation company that supports independent contractors while offering quick and easy auto shipping throughout Europe.
• Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.

Portfolio highlights

• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Commit Biologics — Add a description for facebook
• Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Portfolio highlights

• Yazen — Yazen is a digital obesity clinic that offers weight loss through modern pharmaceutical treatment.
• WithLess — Apps multiply, costs grow, admin spirals. We get it. The tools your team needs WithLess time, money, and admin.
• PIONIX — open source software as a service for charging stations / e-mobility

Portfolio highlights

• Trogenix — Trogenix operates as a therapeutics company, that treats aggressive cancers.
• ViaNautis — Precision Solutions
• SparingVision — We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.

Portfolio highlights

• Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
• Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
• River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.

Portfolio highlights

• Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
• Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
• Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.

Portfolio highlights

• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Ambros Therapeutics — Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases.
• Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.